Naproxen demonstrates a consistently favorable thromboembolic and overall cardiovascular safety profile compared to other non-aspirin NSAIDs due to its low COX-2 selectivity.
The voluntary withdrawal of Vioxx (rofecoxib) from the market in 2004, as well as the 2005 and 2014 US FDA Advisory Committee meetings about non-steroidal anti-inflammatory drugs (NSAIDs) and cardiovascular risk, have raised questions surrounding the use of NSAIDs in at-risk populations. This paper discusses the cardiovascular safety profile of naproxen in the context of the NSAID class. The balance of evidence suggests that cardiovascular risk correlates with cyclooxygenase (COX)-2 selectivity, and the low COX-2 selectivity of naproxen results in a lower cardiovascular risk than that of other NSAIDs. The over-the-counter (OTC) use of naproxen is expected to pose minimal cardiovascular risk; however, the benefit-risk ratio and appropriate use should be considered at an individual patient level, particularly to assess underlying conditions that may increase the risk of events. Likewise, regulatory authorities should revisit label information periodically to ensure labeling reflects the current understanding of benefits and risks.
Angiolillo et al. (Tue,) conducted a review in Musculoskeletal pain and osteoarthritis. Naproxen vs. Other NSAIDs was evaluated. Naproxen demonstrates a consistently favorable thromboembolic and overall cardiovascular safety profile compared to other non-aspirin NSAIDs due to its low COX-2 selectivity.